Thrombin Market Report and Forecast 2025-2034
Description
The global thrombin market size was valued at USD 665.00 Million in 2024, driven by the increasing prevalence of blood disorders such as hemophilia across the globe. The market is expected to grow at a CAGR of 5.50% during the forecast period of 2025-2034, with the values likely to rise from USD 701.3 Million in 2025 to USD 1135.92 Million by 2034.
Global Thrombin Market Overview
Thrombin, also known as coagulation factor II, is a serine protease that regulates hemostasis and maintains blood coagulation. It is naturally produced in humans and is involved in the coagulation cascade. There are three thrombin products: bovine thrombin, human thrombin, and recombinant thrombin. All of them are approved by the Food and Drug Administration (FDA) for topical application as a solution, in combination with fibrinogen as a glue, or sprayed into a mist. As a hemostatic agent, thrombin can minimize blood loss during surgical procedures.
The thrombin market demand is driven by the rising incidence of hemophilia, an inherited bleeding disorder. It is estimated that 1 in every 6000-10,000 males have this bleeding disorder. Approximately 30,000 – 33,000 males are living with hemophilia in the United States, with the highest prevalence found in the Midwestern and Northeastern states. Another key driver is the extensive application of thrombin in the healthcare sector, owing to the growing prevalence of trauma cases. Moreover, the advancement in the healthcare infrastructure as well as the rising disposable income of the population is projected to contribute to the market growth in the forecast period.
Intensive Research to Expedite Thrombin Market Growth
Thrombin is extensively used in the hemostatic field. It can provide a direct clotting effect on the exposed blood, controlling minor oozing and bleeding during surgery. Intensive research activities by academic institutes and pharmaceutical companies revealed several therapeutic applications of thrombin including burn treatment, wound management, and tumor vasculature blockade therapy.
In November 2023, a study published in Nature, compared active (gelatin-thrombin-based product Floseal) and passive (modified absorbable polymers powder PerClot) hemostatic agents to find their effectiveness in controlling hepatic bleeding. It was observed that Floseal (active hemostatic group) was faster to achieve homeostasis than PerClot (passive hemostatic group) which was attributed to the presence of thrombin component in it. The continuous research and development efforts to find novel therapeutics and improve existing uses of thrombin are anticipated to contribute to the thrombin market share.
Growing Applications of Recombinant Thrombin
The regulatory health body FDA has approved many thrombin-based products including recombinant thrombin. Several drugs containing recombinant thrombin are currently undergoing clinical trials for their therapeutic homeostatic effect. In April 2023 , Baxter International Inc., announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. The new addition to its surgical portfolio was revealed at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
Global Thrombin Market Segmentation
The EMR’s report titled “Thrombin Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
North America is experiencing significant growth in the demand for thrombin due to the increasing prevalence of blood disorders and trauma cases which requires the need for effective hemostatic agents. In addition, the robust support from government and non-government organizations is further accelerating market growth.
In August 2023 , Oklahoma Medical Research Foundation scientist Ray Rezaie received a USD 1.7 million grant from the National Institutes of Health (NIH) to support his work on blood clotting and the interaction of associated three molecules including thrombin. The funding will accelerate the research on mechanisms controlling clotting and inflammation, leading to promising medications for stroke, heart attack, and sepsis.
Europe also holds a considerable thrombin market share owing to the presence of well-established healthcare infrastructure. The existence of leading pharmaceutical companies is fuelling research and development (R&D) activities of thrombin, which is expanding the market size. In Asia Pacific, the growing population size, rising healthcare expenditure, and the increasing impetus for improved patient care are driving the market growth. The region is anticipated to offer lucrative growth opportunities for the key market players due to the surge in the adoption of thrombin-based hemostats in healthcare facilities.
Global Thrombin Market: Competitor Landscape
In October 2023 , Aronora, a clinical-stage biotech based in the United States, secured investment from an early-stage life sciences investment fund NYBC Ventures. The funds will be used to develop the lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) and expand its manufacturing capacities. E-WE thrombin, an anticoagulant, has demonstrated positive results in phase 2a clinical trials. The increased investment in research and development by pharmaceutical companies and research organizations will improve the safety and efficacy of thrombin-based products, elevating thrombin market value in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Global Thrombin Market Overview
Thrombin, also known as coagulation factor II, is a serine protease that regulates hemostasis and maintains blood coagulation. It is naturally produced in humans and is involved in the coagulation cascade. There are three thrombin products: bovine thrombin, human thrombin, and recombinant thrombin. All of them are approved by the Food and Drug Administration (FDA) for topical application as a solution, in combination with fibrinogen as a glue, or sprayed into a mist. As a hemostatic agent, thrombin can minimize blood loss during surgical procedures.
The thrombin market demand is driven by the rising incidence of hemophilia, an inherited bleeding disorder. It is estimated that 1 in every 6000-10,000 males have this bleeding disorder. Approximately 30,000 – 33,000 males are living with hemophilia in the United States, with the highest prevalence found in the Midwestern and Northeastern states. Another key driver is the extensive application of thrombin in the healthcare sector, owing to the growing prevalence of trauma cases. Moreover, the advancement in the healthcare infrastructure as well as the rising disposable income of the population is projected to contribute to the market growth in the forecast period.
Intensive Research to Expedite Thrombin Market Growth
Thrombin is extensively used in the hemostatic field. It can provide a direct clotting effect on the exposed blood, controlling minor oozing and bleeding during surgery. Intensive research activities by academic institutes and pharmaceutical companies revealed several therapeutic applications of thrombin including burn treatment, wound management, and tumor vasculature blockade therapy.
In November 2023, a study published in Nature, compared active (gelatin-thrombin-based product Floseal) and passive (modified absorbable polymers powder PerClot) hemostatic agents to find their effectiveness in controlling hepatic bleeding. It was observed that Floseal (active hemostatic group) was faster to achieve homeostasis than PerClot (passive hemostatic group) which was attributed to the presence of thrombin component in it. The continuous research and development efforts to find novel therapeutics and improve existing uses of thrombin are anticipated to contribute to the thrombin market share.
Growing Applications of Recombinant Thrombin
The regulatory health body FDA has approved many thrombin-based products including recombinant thrombin. Several drugs containing recombinant thrombin are currently undergoing clinical trials for their therapeutic homeostatic effect. In April 2023 , Baxter International Inc., announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. The new addition to its surgical portfolio was revealed at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
Global Thrombin Market Segmentation
The EMR’s report titled “Thrombin Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
- Bovine Thrombin
- Human Thrombin
- Recombinant Thrombin
- Powder Form
- Solution Form
- Hospitals
- Diagnostic Centre and Clinics
- Academics and Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
North America is experiencing significant growth in the demand for thrombin due to the increasing prevalence of blood disorders and trauma cases which requires the need for effective hemostatic agents. In addition, the robust support from government and non-government organizations is further accelerating market growth.
In August 2023 , Oklahoma Medical Research Foundation scientist Ray Rezaie received a USD 1.7 million grant from the National Institutes of Health (NIH) to support his work on blood clotting and the interaction of associated three molecules including thrombin. The funding will accelerate the research on mechanisms controlling clotting and inflammation, leading to promising medications for stroke, heart attack, and sepsis.
Europe also holds a considerable thrombin market share owing to the presence of well-established healthcare infrastructure. The existence of leading pharmaceutical companies is fuelling research and development (R&D) activities of thrombin, which is expanding the market size. In Asia Pacific, the growing population size, rising healthcare expenditure, and the increasing impetus for improved patient care are driving the market growth. The region is anticipated to offer lucrative growth opportunities for the key market players due to the surge in the adoption of thrombin-based hemostats in healthcare facilities.
Global Thrombin Market: Competitor Landscape
In October 2023 , Aronora, a clinical-stage biotech based in the United States, secured investment from an early-stage life sciences investment fund NYBC Ventures. The funds will be used to develop the lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) and expand its manufacturing capacities. E-WE thrombin, an anticoagulant, has demonstrated positive results in phase 2a clinical trials. The increased investment in research and development by pharmaceutical companies and research organizations will improve the safety and efficacy of thrombin-based products, elevating thrombin market value in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Johnson and Johnson
- Baxter International, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- Japan Blood Products Organization
- Mochida Pharmaceutical Co., Ltd
- Haematologic Technologies Inc.
- GE Healthcare
- Hualan Biological
- AMRESCO Inc
- CSL Behring
- Mallinckrodt Pharmaceuticals
- BIOFAC A/S
- Biomed-Lublin S.A.
- Hualan Biological Engineering, Inc.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Thrombin Market Overview
- 3.1 Global Thrombin Market Historical Value (2018-2024)
- 3.2 Global Thrombin Market Forecast Value (2025-2034)
- 4 Global Thrombin Market Landscape*
- 4.1 Global Thrombin Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Thrombin Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Dosage Form
- 5 Global Thrombin Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Thrombin Market Segmentation (218-2034)
- 6.1 Global Thrombin Market (2018-2034) by Product
- 6.1.1 Market Overview
- 6.1.2 Bovine Thrombin
- 6.1.3 Human Thrombin
- 6.1.4 Recombinant Thrombin
- 6.2 Global Thrombin Market (2018-2034) by Dosage Form
- 6.2.1 Market Overview
- 6.2.2 Powder Form
- 6.2.3 Solution Form
- 6.3 Global Thrombin Market (2018-2034) by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Diagnostic Centre and Clinics
- 6.3.4 Academics and Research Institutes
- 6.3.5 Others
- 6.4 Global Thrombin Market (2018-2034) by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Thrombin Market (218-2034)
- 7.1 North America Thrombin Market (2018-2034) by Product
- 7.1.1 Market Overview
- 7.1.2 Bovine Thrombin
- 7.1.3 Human Thrombin
- 7.1.4 Recombinant Thrombin
- 7.2 North America Thrombin Market (2018-2034) by Dosage Form
- 7.2.1 Market Overview
- 7.2.2 Powder Form
- 7.2.3 Solution Form
- 7.3 North America Interventional Radiology Market (2018-2034) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Thrombin Market (218-2034)
- 8.1 Europe Thrombin Market (2018-2034) by Product
- 8.1.1 Market Overview
- 8.1.2 Bovine Thrombin
- 8.1.3 Human Thrombin
- 8.1.4 Recombinant Thrombin
- 8.2 Europe Thrombin Market (2018-2034) by Dosage Form
- 8.2.1 Market Overview
- 8.2.2 Powder Form
- 8.2.3 Solution Form
- 8.3 Europe Thrombin Market (2018-2034) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Thrombin Market (218-2034)
- 9.1 Asia Pacific Thrombin Market (2018-2034) by Product
- 9.1.1 Market Overview
- 9.1.2 Bovine Thrombin
- 9.1.3 Human Thrombin
- 9.1.4 Recombinant Thrombin
- 9.2 Asia Pacific Thrombin Market (2018-2034) by Dosage Form
- 9.2.1 Market Overview
- 9.2.2 Powder Form
- 9.2.3 Solution Form
- 9.3 Asia Pacific Cryostat Market (2018-2034) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Thrombin Market (218-2034)
- 10.1 Latin America Thrombin Market (2018-2034) by Product
- 10.1.1 Market Overview
- 10.1.2 Bovine Thrombin
- 10.1.3 Human Thrombin
- 10.1.4 Recombinant Thrombin
- 10.2 Latin America Thrombin Market (2018-2034) by Dosage Form
- 10.2.1 Market Overview
- 10.2.2 Powder Form
- 10.2.3 Solution Form
- 10.3 Latin America Thrombin Market (2018-2034) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Thrombin Market (218-2034)
- 11.1 Middle East and Africa Thrombin Market (2018-2034) by Product
- 11.1.1 Market Overview
- 11.1.2 Bovine Thrombin
- 11.1.3 Human Thrombin
- 11.1.4 Recombinant Thrombin
- 11.2 Middle East and Africa Thrombin Market (2018-2034) by Dosage Form
- 11.2.1 Market Overview
- 11.2.2 Powder Form
- 11.2.3 Solution Form
- 11.3 Middle East and Africa Interventional Radiology Market (2018-2034) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Pfizer Inc.
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Johnson and Johnson
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Baxter International, Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Shanghai RAAS Blood Products Co., Ltd.
- 17.4.1 Financial Analysis
- 17.4.2 Financial Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Japan Blood Products Organization
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Mochida Pharmaceutical Co., Ltd
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Haematologic Technologies Inc.
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 GE Healthcare
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Hualan Biological
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 AMRESCO Inc
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 CSL Behring
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Mallinckrodt Pharmaceuticals
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 BIOFAC A/S
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Biomed-Lublin S.A.
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Hualan Biological Engineering, Inc.
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
